Estimating the natural progression of non-invasive ductal carcinoma in situ breast cancer lesions using screening data.
Harald Weedon-FekjærXiaoxue LiSandra LeePublished in: Journal of medical screening (2020)
Most preclinical DCIS lesions progress or regress with a moderate sojourn time in the screening-detectable phase. While DCIS mean sojourn time could be deduced from DCIS data, any estimate of preclinical DCIS progressing to invasive breast cancer must include data on invasive cancers to avoid strong, probably unrealistic, assumptions.